|
|
|
|
| LEADER |
00000cam a2200000Mu 4500 |
| 001 |
EBSCO_on1227390671 |
| 003 |
OCoLC |
| 005 |
20231017213018.0 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
201219s2020 si o ||| 0 eng d |
| 040 |
|
|
|a EBLCP
|b eng
|c EBLCP
|d EBLCP
|d N$T
|d OCLCF
|d OCLCO
|d K6U
|d OCLCQ
|d OCLCO
|
| 066 |
|
|
|c (S
|
| 020 |
|
|
|a 9811469555
|
| 020 |
|
|
|a 9789811469558
|q (electronic bk.)
|
| 029 |
1 |
|
|a AU@
|b 000071377516
|
| 035 |
|
|
|a (OCoLC)1227390671
|
| 050 |
|
4 |
|a RB145
|
| 082 |
0 |
4 |
|a 616.15
|2 23
|
| 049 |
|
|
|a UAMI
|
| 100 |
1 |
|
|a Atta-ur-Rahman.
|
| 245 |
1 |
0 |
|a Frontiers in Clinical Drug Research - Hematology
|h [electronic resource].
|
| 260 |
|
|
|a Singapore :
|b Bentham Science Publishers,
|c 2020.
|
| 300 |
|
|
|a 1 online resource (267 p.).
|
| 490 |
1 |
|
|a Frontiers in Clinical Drug Research - Hematology Ser.
|
| 500 |
|
|
|a Description based upon print version of record.
|
| 505 |
0 |
|
|a Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Preface -- List of Contributors -- TRP Channels: Potential Therapeutic Targets in Blood Disorders -- Amritlal Mandal* -- INTRODUCTION -- TRP CHANNELS IN BLOOD DISORDERS -- TRP Channels and Abnormalities in RBCs -- Sickle Cell Disease (SCD) -- TRP Channels in Platelets Related Disorders -- TRPML and Iron-deficiency Anaemia -- TRPM6 in Dysregulated Blood and Serum Mg2+ Homeostasis -- TRP Channels and Hematological Malignancies -- TRPM Channels -- TRPM1 -- TRPM2 -- TRPM4 -- TRPM5 -- TRPM7 -- TRPM8 -- TRPV Channels -- TRPV1
|
| 505 |
8 |
|
|a Leukemia Cell Lines -- Adult T-Cell Leukemia (ATL) -- Multiple Myeloma (MM) -- TRPV2 -- TRPV5 and TRPV6 -- TRPC Channels -- TRPC1 -- TRPC2, TRPC3 and TRPC6 -- TRPC7 -- TRPP Channels -- CONCLUSIONS AND FUTURE DIRECTION -- ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Hypercoagulable States: Clinical Symptoms, Laboratory Markers and Management -- Pusparini Pusparini1 and Adi Hidayat2,* -- INTRODUCTION -- CLINICAL SYMPTOMS -- Venous Thromboembolism (VTE) -- Pathophysiology -- Clinical Presentation -- Evaluation -- Arterial Thromboembolism
|
| 505 |
8 |
|
|a Protein S Deficiency -- Pathophysiology -- Epidemiology -- Laboratory Tests -- Management -- Antithrombin Deficiency -- Laboratory Tests -- Hyperhomocysteinemia -- Management -- Elevated Factor VIII -- Dysfibrinogenemia -- ALGORITHMIC APPROACH TO LABORATORY TESTING -- Patient Selection -- Reason to Test -- The "4P" Approach -- Whom to Test -- Whom Not to Test -- Points to Consider in Requests for Laboratory Examinations -- MANAGEMENT -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES
|
| 500 |
|
|
|a CURRENT CHALLENGES AND FUTURE OUTLOOK.
|
| 590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
| 650 |
|
0 |
|a Metabolism
|x Disorders.
|
| 650 |
|
2 |
|a Metabolic Diseases
|
| 650 |
|
6 |
|a Troubles du métabolisme.
|
| 650 |
|
7 |
|a Metabolism
|x Disorders
|2 fast
|
| 776 |
0 |
8 |
|i Print version:
|a Atta-ur-Rahman
|t Frontiers in Clinical Drug Research - Hematology: Volume 4
|d Singapore : Bentham Science Publishers,c2020
|z 9789811469534
|
| 830 |
|
0 |
|a Frontiers in Clinical Drug Research - Hematology Ser.
|
| 856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=2700845
|z Texto completo
|
| 880 |
8 |
|
|6 505-00/(S
|a Advanced Applications of Gene Therapy in the Treatment of Haematologic Disorders -- Mayasah Al-Nema and Anand Gaurav* -- INTRODUCTION -- GENE THERAPY TECHNIQUES USED IN THE TREATMENT OF BLOOD DISORDERS -- Gene Delivery Viral Vectors -- Haemophilia -- β-Haemoglobinopathies -- Genome Editing Technology (CRISPR-Cas9) -- How Does CRISPR Work in Bacteria-- Application of CRISPR-Cas9 in β-Haemoglobinopathies and Fanconi Anaemia -- Chimeric Antigen Receptor (CAR) T-Cell Therapy -- CAR T-Cell Therapy for Haematological Malignancies -- CAR Modified-Hematopoietic Stem Cells
|
| 880 |
8 |
|
|6 505-00/(S
|a Recurrent Venous Thromboembolism -- Risk Factors of Recurrent VTE -- RISK FACTORS/PREDISPOSING FACTORS -- Management -- HYPERCOAGULABLE DISORDERS -- Antiphospholipid Syndrome -- Lupus Anticoagulant Testing -- Anticardiolipin and β2GPI Antibody Testing -- Management -- Venous Thrombotic Events -- Direct Oral Anticoagulants (DOACs) -- Non-Anticoagulant Treatment of Thrombotic APS -- Factor V Leiden Mutation and Activated Protein C Resistance -- Factor V Leiden (FVL) -- Management -- Prothrombin Gene G20210A Mutations -- Management -- Protein C Deficiency -- Pathophysiology -- Management
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL6424224
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 2700845
|
| 994 |
|
|
|a 92
|b IZTAP
|
